Carlsbad’s Ionis strikes deal with Japanese pharma worth up to $940M
Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...
BioSpace13d
Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...
BioPharma Dive13d
Ono pays $280M to license Ionis rare disease drug
Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.
Business Wire14d
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license a ...
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.
Yahoo Finance14d
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Ionis is also eligible to earn royalties in ... president and COO, Ono. About Polycythemia Vera (PV) PV is a rare and potentially life-threatening hematologic disease characterized by the ...
Morningstar14d
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Ionis Pharmaceuticals ... an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease. Sapablursen is currently being evaluated ...